Orthovita, Inc., a specialty spine and orthopedic company, develops and markets orthobiologic and biosurgery products. The companys orthobiologics platform offers products for the fusion, regeneration, and fixation of human bone; and the biosurgery platform provides products for controlling intra-operative bleeding/hemostasis. Its orthobiologic product portfolio comprises Vitoss bone graft substitute, a high-porous resorbable beta-tricalcium phosphate bone graft substitute used to help the body guide the three-dimensional regeneration of the patients own bone; Bone Marrow Aspiration System with imbibe needles, syringes, and imbibe disposable delivery instrumentation, which provides spine and orthopedic surgeons with a method for harvesting a patients own bone marrow; Cortoss Bone Augmentation Material, a polymer composite for use in various surgical procedures to provide structural stability and reinforcement of the bones after surgery; and Aliquot Delivery System that facilitates delivery of materials to bony sites, including delivery of Cortoss product directly to the surgical site. The companys biosugery products include Vitagel surgical hemostat, a composite liquid hemostat that combines the biomaterials bovine thrombin and bovine collagen with the patients autologous plasma, and applied in the spine, hip, and knee replacement surgeries; and Vitasure Absorbable Hemostat, a plant-based hemostat product that can be deployed throughout surgery. It sells its products in the United States and internationally through a network of direct sales representatives and independent non-stocking distributors. The company has strategic partnerships with Kensey Nash Corporation; Angiotech Pharmaceuticals (U.S.), Inc.; and Medafor, Inc. Orthovita was founded in 1992 and is headquartered in Malvern, Pennsylvania.